Becton Dickinson 

€212.8
491
+€0.5+0.24% Friday 06:06

统计数据

当日最高
-
当日最低
-
52周最高
-
52周最低
-
成交量
-
平均成交量
-
市值
17.17B
市盈率
-
股息收益率
1.62%
股息
3.45

即将到来

股息

1.62%股息收益率
10年增长
N/A
5年增长
N/A
3年增长
N/A
1年增长
N/A

收益

7Nov已确认
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
下一个
2.4
2.86
3.33
3.79
预期每股收益
3.794103
实际每股收益
N/A

人们还关注

此列表基于关注BOX.F的Stock Events用户的观察列表。这不是投资建议。

竞争者

这个列表是基于最近市场事件的分析。这不是投资建议。
Medtronic
MDT
市值105.2B
Medtronic在医疗器械领域与Becton Dickinson直接竞争,尤其是在外科手术器械和糖尿病护理产品等领域。
Abbott Laboratories
ABT
市值189.14B
Abbott Laboratories提供了一系列与Becton Dickinson的产品竞争的医疗设备、诊断和营养产品。
Thermo Fisher Scientific
TMO
市值227.74B
赛默飞世尔科技公司在实验室设备和耗材供应方面与贝克顿迪金森的生命科学部门直接竞争。
Danaher
DHR
市值193.63B
Danaher Corporation的生命科学和诊断部门提供与Becton Dickinson的产品组合竞争的产品,尤其是在诊断和研究领域。
Stryker
SYK
市值124.93B
Stryker Corporation是医疗技术领域的竞争对手,尤其在外科手术设备和医院床位方面,这也是Becton Dickinson的业务领域。
Boston Scientific
BSX
市值112.2B
波士顿科学公司在医疗器械市场上与贝克顿·迪金森竞争,尤其是在心血管和内窥镜产品等领域。
Johnson & Johnson
JNJ
市值386.65B
强生公司的医疗器械部门提供的产品在多个贝克顿·迪金森的关键领域中竞争,包括外科手术器械和感染预防。
Hologic
HOLX
市值19.43B
Hologic, Inc. 在诊断和妇女健康领域与Becton Dickinson竞争,提供类似的癌症检测和手术产品。
Zimmer Biomet
ZBH
市值22.01B
Zimmer Biomet Holdings, Inc. 在肌肉骨骼保健领域与Becton Dickinson的手术和康复产品解决方案产生竞争。
Intuitive Surgical
ISRG
市值164.68B
Intuitive Surgical, Inc.在外科手术器械市场上与Becton Dickinson竞争,尤其是其机器人辅助外科手术系统。

关于

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Show more...
首席执行官
Mr. Thomas E. Polen Jr.
员工
70000
国家
US
ISIN
US0758871091
WKN
000857675

上市公司